Costco Wholesale Corporation (COST)
Costco Wholesale Corporation (COST) is one of the top 5 largest retailers in the United States, a chain of self-service club-type warehouses.
The company Costco made a bet on high sales and increased turnover, reducing the price of goods. The cost of goods is lower than that of other wholesale suppliers. High throughput is ensured by the fact that the network stores are open seven days a week.
Huge buying power: 62.5 million households are members of the Costco Club, and its excellent pricing policy generates good deals with suppliers and multiplies the company’s revenues. In 2021 Costco’s revenue was $ 196 billion, in early 2022 sales were up 15.5%, even in the worst of times, the company maintains a high rating with consumers.
Even now, when inflation hit record highs in the U.S. the company has kept buyers interested, although the company’s shares, like many others, sagged in value and traded at $446.69 after an April peak of $598.
Analysts predict the stock will rise further to $542.
High employee salaries are also boosting confidence in the issuer.
Costco is of interest to investors, despite the fact that the stock has a rather high price. P/E ratio equals 47.35, which is quite comparable to the shares of Walmart and Amazon. The company’s net income, held almost at the same level, despite the global macroeconomic headwinds.
NEX is up 207% since the beginning of the year.
McKesson Corporation ( MCK )
McKesson, one of the largest manufacturers of equipment and supplies, is a provider of medical essentials to surgical centers, medical centers and hospitals nationwide. The company engages in the wholesale sourcing, distribution and dispensing of pharmaceutical and medical products, contract manufacturing and related IT services to acute care hospitals and health systems, independent and chain retail pharmacies in North America, Europe and Canada.
These include medicines and high-tech surgical instruments. Healthcare companies are seen as recession-proof because the need for healthcare will remain strong in any environment. Offers MCK proposed to shareholders are designed to diversify risk and to bring stable income, despite the recession in the world economy.
MCK stock trades at $300, down from $337 late last month. Analysts’ target price is increasing and is projected to rise to $368 year-over-year.
For the fiscal year ended March 31, 2022, McKesson Corporation’s revenue rose 11% to $263.97 billion. Net income before extraordinary items was $1.12 billion versus a loss of $4.54 billion. Revenues reflect a 12% increase in the U.S. pharmaceutical segment to $212.15 billion, a 15% increase in the medical-surgical solutions segment to $11.61 billion, and a 34% increase in the prescription technology segment to $3.86 billion.
Aadi Bioscience Inc.
Aadi Bioscience Inc. is a clinical-stage biopharmaceutical company that develops innovative treatments for genetically determined cancers. The CEO of Aadi Bioscience Inc.is Neil P. Desai .
Aadi’s main goal is to provide transformative therapies for cancer patients with changes in the mTOR pathway driver, such as changes in the TSC1 or TSC2 genes, where other mTOR inhibitors cannot or cannot be used effectively due to pharmacological, effective drug delivery, safety or efficacy issues. The company’s developments appear extremely promising to investors
Shares of Aadi Bioscience Inc. closed at 13.65 per share at the end of the last trading day (up 6.56% from the previous day’s closing price) on volume of 415,800 shares and a market capitalization of 285.84 million . It is a component of indices and traded on the NASDAQ .
The consensus rating by Wall Street analysts for Aadi Bioscience Inc. – “Strong Buy” with a target price of $43.5 , compared to the current price this is +218.68%
Latest News